- Verdugo-Sivianes, Eva M.
- Martínez-Pérez, Julia
- Navas, Lola E.
- Sáez, Carmen
- Carnero, Amancio
This article belongs to the Section Molecular Cancer Biology., [Data Availability Statement]
Data from publicly available clinical and genomic information were obtained from the R2 Genomics analysis and visualization platform (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi; accessed on January 2025), the TCGA Research Network (https://cancergenome.nih.gov/; accessed on November 2022) and the TISCH resource (http://tisch1.comp-genomics.org/; accessed on November 2022) [25]., [Simple Summary]
Pancreatic cancer (PC) is the seventh leading cause of cancer-related deaths globally, marked by a high mortality due to its aggressive nature and late diagnosis. Although surgical resection is the only curative option, most cases are diagnosed too late for surgery. This study identifies potential treatment vulnerabilities by focusing on MAP17 (PDZK1IP1), whose high mRNA expression correlates with poor prognosis and is found exclusively in tumor cells. In 2D cultures, MAP17-expressing cells responded better to gemcitabine and 5-fluorouracil. However, in vivo xenograft models showed resistance to all treatments. These cells also had elevated NAD levels, which could be depleted using NAMPT inhibitors. Indeed, depletion of NAD seems to resensitize MAP17-expressing tumors to chemotherapy. Thus, MAP17 may serve as a prognostic marker and therapeutic target. Combining NAMPT inhibitors with standard therapies could enhance treatment efficacy in patients with high MAP17 expression., [Background/Objectives:]
Pancreatic cancer (PC) is the seventh leading cause of cancer-related deaths worldwide, with its incidence rising each year. Despite its relatively low incidence, the aggressiveness of pancreatic cancer results in high mortality, with only 12% of patients surviving five years post-diagnosis. Surgical resection remains the only potentially curative treatment, but the tumor is often diagnosed at an advanced stage. The goal of this work is to identify vulnerabilities that can affect the efficacy of treatments and improve the efficacy of therapy., [Methods:]
MAP17 overexpression in pancreatic cancer cell lines, RT-qPCR analysis, xenografts, in vitro and in vivo treatments, analysis of data from pancreatic tumors in transcriptomic patient databases., [Results:]
We studied the prognostic and predictive value of MAP17 (PDZK1IP1) expression in pancreatic cancer, and we found that high MAP17 mRNA expression was associated with poor prognosis. In addition, single-cell analysis revealed that high MAP17 expression was present only in tumor cells. We investigated whether the response to various antitumor agents depended on MAP17 expression. In 2D culture, MAP17-expressing pancreatic cancer cells responded better to gemcitabine and 5-fluorouracil. However, in vivo xenograft tumors with MAP17 expression showed resistance to all treatments. Additionally, MAP17-expressing cells had a high NAD pool, which seems to be effectively depleted in vivo by NAMPT inhibitors, the primary enzyme for NAD biosynthesis., [Conclusions:]
Our findings suggest that MAP17 expression could enhance the prognostic stratification of pancreatic cancer patients. Moreover, the coadministration of NAMPT inhibitors with current treatments may sensitize tumors with high MAP17 expression to chemotherapy and improve the efficacy of chemotherapy., This work was supported by grants from the Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I+D+I 2018, Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): RTI2018-097455-B-I00, and a PID2021-122629OB-I00 grant from AEI-MICIU/FEDER (RED2018-102723-T); from CIBER de Cáncer (CB16/12/00275), co-funded by FEDER from Regional Development European Funds (European Union); from Consejería de Salud (PI-0397-2017) and from Consejería de Economía, Conocimiento, Empresas y Universidad de la Junta de Andalucía (P18-RT-2501). Special thanks to the AECC Foundation (Spanish Association of Cancer Research) for supporting this work (founding ref. GC16173720CARR). EMV-S was funded by a postdoctoral contract from Consejería de Transformación Económica, Industria, Conocimiento, y Universidades de la Junta de Andalucía, Spain (CTEICU/PAIDI 2020, DOC_01655). JM-P was funded by a Rio Hortega contract from Instituto de Salud Carlos III (ISCIII, CM18/00219). We also thanks the COST action TRANSPAN (Action CA21116). The funders played no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer reviewed